Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute, Charlotte, NC, provides an overview of the latest trial updates presented at ASH 2020 for several B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies for multiple myeloma. He also discusses the promise of off-the-shelf allogeneic CAR T-cell therapies but considers the potential obstacles related to this treatment modality. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.